Holen Sie sich die Stockscreener-App
38.40
3.53%
1.31
Vorhandelsmarkt:
38.99
0.59
+1.54%
Schlusskurs vom Vortag:
$37.09
Offen:
$37.75
24-Stunden-Volumen:
13.35M
Relative Volume:
0.48
Marktkapitalisierung:
$8.42B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
55.65
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+7.17%
1M Leistung:
-21.28%
6M Leistung:
-29.97%
1J Leistung:
+25.16%
1-Tages-Spanne:
$37.36
$38.79
1-Wochen-Bereich:
$32.88
$38.79
52-Wochen-Spanne:
$23.97
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
38.40 | 8.44B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
127.69 | 56.36B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.52 | 45.81B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.76 | 43.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
26.32 | 28.67B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
488.43 | 20.92B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Market Challenges - Quiver Quantitative
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip? - Nasdaq
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Why Hims & Hers moved into lab testing - Healthcare Brew
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform - Seeking Alpha
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve - Yahoo Finance
Hims & Hers Health (HIMS) Launches $250 Million Buyback Amid Stock Slide - Somos Hermanos -
Assessing Hims & Hers Health After Latest Partnerships and a 50% Year-to-Date Price Surge - Yahoo Finance
Hims, Block, and NRG Just Launched Huge Stock Buybacks - Finviz
Alignment Healthcare, Hims & Hers Health, Surgery Partners, Guardant Health, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know - Finviz
Hims & Hers: The Growth Story Is Outside GLP-1s - Seeking Alpha
1 Small-Cap Stock with Exciting Potential and 2 We Avoid - Finviz
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? - The Motley Fool
Hims & Hers Health (NYSE:HIMS) Could Easily Take On More Debt - 富途牛牛
Hims & Hers health authorizes $250 million share repurchase program - MSN
How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge - Bloomberg.com
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model - Yahoo Finance
Hims & Hers Health Options Trading: A Deep Dive into Market Sentiment - Benzinga
OMCL or HIMS: Which Is the Better Value Stock Right Now? - sharewise.com
Hims & Hers Health: A Notable Shift Toward Core - Smartkarma
Hims & Hers Health Announces New Share Buyback Program - MSN
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? - MarketBeat
Hims & Hers Health Insider Sold Shares Worth $853,490, According to a Recent SEC Filing - MarketScreener
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Competitive Challenges - Quiver Quantitative
Hers Health Inc. stock surprise with earnings upside2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS) - The Globe and Mail
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell? - Finviz
Parents Sue Hims After Washington State Student’s Suicide - USA Herald
Commit To Purchase Hims & Hers Health At $20, Earn 27.2% Using Options - Nasdaq
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29% - simplywall.st
Telehealth Co. Hims Sued Over College Student's Suicide - Law360
Key facts: Hims & Hers shares fall 4.9%; Deb Autor appointed Chief Policy Officer - TradingView
Hims & Hers Stock Falls Amid Weight-Loss Drug Price CompetitionNews and Statistics - IndexBox
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - Finviz
What's Going On With Hims & Hers Health Shares Monday? - Benzinga
Hims & Hers Health board approves $250 million share repurchase program - Investing.com Nigeria
Hims & Hers Health stock rises after announcing $250 million buyback program - MSN
Hims & Hers names ex-FDA official Deb Autor as first policy chief - Reuters
Hims & Hers Health, Inc. Appoints Deb Autor as the First Chief Policy Officer - MarketScreener
Hims & Hers Announces New $250 Million Share Repurchase Program – Retail Sees A Steady Trading Range For The Stock - Stocktwits
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% - MSN
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE) - Seeking Alpha
Hims & Hers announces $250 million share repurchase program - Investing.com India
Hims & Hers Health Announces New Share Repurchase Program - TradingView
[8-K] Hims & Hers Health, Inc. Reports Material Event | HIMS SEC FilingForm 8-K - Stock Titan
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization - Hims Investor Relations
Hims & Hers appoints former FDA leader Deb Autor as first CPO - Investing.com Canada
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy - The AI Journal
Hims & Hers appoints former FDA leader Deb Autor as first CPO By Investing.com - Investing.com South Africa
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):